Bold claim: new EU drug legislation could cut off life-saving medicines from patients. And this is where the stakes get real. Dutch pharmacists warn that a recently proposed European Union framework threatens the steady availability of essential medicines, particularly those produced by compounding pharmacies. In acute care settings—emergency rooms, intensive care units, and operating rooms—delays or shortages can be life-or-death. The Dutch Association of Hospital Pharmacists (NVZA), the Royal Dutch Pharmacists Association (KNMP), and the Network of Specialized Compounding Pharmacies (NGB) express deep concern that the new rules may restrict compounding pharmacies from supplying medicines to other pharmacies, undermining the broader supply chain.
Compounding pharmacies create customized drugs that aren’t available from standard manufacturers. They tailor formulations for children, patients with rare conditions, and those in critical need. They also step in during shortages to keep essential treatments reachable. If the new EU legislation limits this collegial supply, patients—whether adults or children—could face dangerous gaps in access, especially in high-stakes environments where rapid administration is crucial, according to Claartje Samson, chair of NVZA, in an interview with NOS.
Among the affected medicines are vital treatments such as flucytosine for severe fungal infections and various liquid formulations used for pediatric sedation, epilepsy management, or blood pressure support in stabilized patients.
Think of a scenario: a patient experiencing severe bleeding or a life-threatening infection slips into shock. Immediate access to the right drug can stabilize blood pressure and heart rate and prevent deterioration. The risk of not being able to obtain these medicines is a real concern for clinicians and patients alike, Samson notes.
In the Netherlands today, collegial supply is tolerated under national rules but not explicitly guaranteed by EU law. Dutch caretaker Health Minister Robbert D. Bruijn is actively engaging in Brussels to preserve this practice, arguing that patients must receive the medications they require when they need them.
We’ll watch how negotiations unfold, but the core message remains clear: ensure reliable access to lifesaving medicines by safeguarding collaborative, cross-supply arrangements across the EU—and ask yourself what this means for patient outcomes if such flexibility is restricted. Should policymakers prioritize rigid compliance over practical patient welfare? How might different countries balance regulatory clarity with the urgent needs of clinical care? Share your thoughts in the comments.
